Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.

NCT02681523 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT02681523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02681523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Terminated
Start date
October 28, 2015
Completion date
July 24, 2018
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer